EMA Authorised: Tysabri (natalizumab) — Biogen Netherlands B.V.

View source ↗

Summary

European Medicines Agency authorises Tysabri (natalizumab) for multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Biogen Netherlands B.V.. Decision date: 18/06/2026